Patent ID: 7879793

Claim:
A method of treating one or more of sepsis, thrombosis, and systemic inflammatory reaction syndrome (SIRS) in an individual, comprising delivering to the individual a therapeutically effective amount of an A2 domain of von Willebrand factor, or a functionally active fragment of said A2 domain, wherein said A2 domain of von Willebrand factor or said functionally active fragment of said A2 domain is further defined as a polypeptide comprising at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, at least 97% identity, at least 98% identity, or at least 99% identity to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:30 that inhibits ristocetin-induced platelet agglutination, shear-induced platelet aggregation, and platelet adhesion to collagen under flow conditions.